After more than 10 years of use, rituximab has proven to be remarkably safe. However,
accumulated evidence now suggests that under some circumstances it may significantly …

Rituximab is a chimeric monoclonal antibody used to treat hematologic and autoimmune
diseases by depleting CD20-expressing B cells. Patients may develop …

Secondary hypogammaglobulinemia (SHG) is characterized by reduced immunoglobulin
levels due to acquired causes of decreased antibody production or increased antibody loss …

Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and
autoimmune disease. Hypogammaglobulinemia has occurred after rituximab for lymphoma …

Background Rituximab has altered the treatment approach to B-cell malignancies and other
diseases. Reports consider that rituximab had limited impact on serum immunoglobulins …

Background Rituximab is a B cell depleting anti-CD20 monoclonal antibody. CD20 is not
expressed on mature plasma cells and accordingly rituximab does not have immediate …

Background: Rituximab, a chimeric monoclonal antibody against CD20, is increasingly used
in the treatment of B-cell lymphomas and autoimmune conditions. Transient peripheral B …

Rituximab is a B cell depleting monoclonal antibody that targets the B cell-specific cell
surface antigen CD20 and is currently used to treat several autoimmune diseases. The …

In a previous systematic review and meta-analysis of five randomized controlled trials
comparing rituximab maintenance with no maintenance (observation or rituximab at …

Purpose The objective of this randomized trial was to assess the efficacy and safety of
rituximab as in vivo purging before transplantation and as maintenance treatment …